T 1796/22 (Everolimus and pancreatic tumours/NOVARTIS) of 26.09.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T179622.20230926
- Date of decision
- 26 September 2023
- Case number
- T 1796/22
- Petition for review of
- -
- Application number
- 18155724.0
- IPC class
- A61P 35/00A61K 31/436
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- RAPAMYCIN DERIVATIVE FOR TREATING PANCREAS CANCER
- Applicant name
- Novartis Pharma AG
- Opponent name
- STADA Arzneimittel AG
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
BIOGARAN
Ethypharm
Zentiva k.s.
Teva Pharmaceutical Industries Ltd.
ARROW GENERIQUES - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 100(c)
- Keywords
- Grounds for opposition - added subject-matter (no)
Grounds for opposition - insufficiency of disclosure (no)
Grounds for opposition - lack of inventive step (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is maintained as granted.